Effect of lomefloxacin on theophylline pharmacokinetics

David E. Nix, A. Norman, J. J. Schentag

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

A study involving 25 healthy male volunteers was conducted to evaluate the effect of lomefloxacin on the pharmacokinetics of theophylline. The mean age was 22.4 ± 3.0 years, and the mean weight was 77.3 ± 7.7 kg. A single 6-mg/kg aminophylline dose was given intravenously on study days 1 and 15. The subjects received a 400-mg lomefloxacin dose (four 100-mg capsules) on study days 9 through 15. No treatment was given on study days 2 through 8. Thirteen blood samples were collected within 24 h after each aminophylline dose. Theophylline concentration in serum were measured by enzyme immunoassay (EMIT). The mean aminophylline dose was 437 ± 36 mg, equivalent to 344 mg of theophylline. Multiple doses of lomefloxacin had no effect on the area under the concentration-time curve from 0 h to infinity, maximal concentration, or clearance of theophylline from serum. There was a slight increase in the theophylline half-life from 6.72 ± 1.63 to 7.02 ± 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant. No change in theophylline dose is required when lomefloxacin therapy is instituted in a patient receiving theophylline.

Original languageEnglish (US)
Pages (from-to)1006-1008
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume33
Issue number7
StatePublished - 1989
Externally publishedYes

Fingerprint

Theophylline
Pharmacokinetics
Aminophylline
lomefloxacin
Serum
Immunoenzyme Techniques
Capsules
Half-Life
Healthy Volunteers
Weights and Measures
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effect of lomefloxacin on theophylline pharmacokinetics. / Nix, David E.; Norman, A.; Schentag, J. J.

In: Antimicrobial Agents and Chemotherapy, Vol. 33, No. 7, 1989, p. 1006-1008.

Research output: Contribution to journalArticle

Nix, DE, Norman, A & Schentag, JJ 1989, 'Effect of lomefloxacin on theophylline pharmacokinetics', Antimicrobial Agents and Chemotherapy, vol. 33, no. 7, pp. 1006-1008.
Nix, David E. ; Norman, A. ; Schentag, J. J. / Effect of lomefloxacin on theophylline pharmacokinetics. In: Antimicrobial Agents and Chemotherapy. 1989 ; Vol. 33, No. 7. pp. 1006-1008.
@article{3746f60a01b14b49940558873a7cb2af,
title = "Effect of lomefloxacin on theophylline pharmacokinetics",
abstract = "A study involving 25 healthy male volunteers was conducted to evaluate the effect of lomefloxacin on the pharmacokinetics of theophylline. The mean age was 22.4 ± 3.0 years, and the mean weight was 77.3 ± 7.7 kg. A single 6-mg/kg aminophylline dose was given intravenously on study days 1 and 15. The subjects received a 400-mg lomefloxacin dose (four 100-mg capsules) on study days 9 through 15. No treatment was given on study days 2 through 8. Thirteen blood samples were collected within 24 h after each aminophylline dose. Theophylline concentration in serum were measured by enzyme immunoassay (EMIT). The mean aminophylline dose was 437 ± 36 mg, equivalent to 344 mg of theophylline. Multiple doses of lomefloxacin had no effect on the area under the concentration-time curve from 0 h to infinity, maximal concentration, or clearance of theophylline from serum. There was a slight increase in the theophylline half-life from 6.72 ± 1.63 to 7.02 ± 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant. No change in theophylline dose is required when lomefloxacin therapy is instituted in a patient receiving theophylline.",
author = "Nix, {David E.} and A. Norman and Schentag, {J. J.}",
year = "1989",
language = "English (US)",
volume = "33",
pages = "1006--1008",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - Effect of lomefloxacin on theophylline pharmacokinetics

AU - Nix, David E.

AU - Norman, A.

AU - Schentag, J. J.

PY - 1989

Y1 - 1989

N2 - A study involving 25 healthy male volunteers was conducted to evaluate the effect of lomefloxacin on the pharmacokinetics of theophylline. The mean age was 22.4 ± 3.0 years, and the mean weight was 77.3 ± 7.7 kg. A single 6-mg/kg aminophylline dose was given intravenously on study days 1 and 15. The subjects received a 400-mg lomefloxacin dose (four 100-mg capsules) on study days 9 through 15. No treatment was given on study days 2 through 8. Thirteen blood samples were collected within 24 h after each aminophylline dose. Theophylline concentration in serum were measured by enzyme immunoassay (EMIT). The mean aminophylline dose was 437 ± 36 mg, equivalent to 344 mg of theophylline. Multiple doses of lomefloxacin had no effect on the area under the concentration-time curve from 0 h to infinity, maximal concentration, or clearance of theophylline from serum. There was a slight increase in the theophylline half-life from 6.72 ± 1.63 to 7.02 ± 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant. No change in theophylline dose is required when lomefloxacin therapy is instituted in a patient receiving theophylline.

AB - A study involving 25 healthy male volunteers was conducted to evaluate the effect of lomefloxacin on the pharmacokinetics of theophylline. The mean age was 22.4 ± 3.0 years, and the mean weight was 77.3 ± 7.7 kg. A single 6-mg/kg aminophylline dose was given intravenously on study days 1 and 15. The subjects received a 400-mg lomefloxacin dose (four 100-mg capsules) on study days 9 through 15. No treatment was given on study days 2 through 8. Thirteen blood samples were collected within 24 h after each aminophylline dose. Theophylline concentration in serum were measured by enzyme immunoassay (EMIT). The mean aminophylline dose was 437 ± 36 mg, equivalent to 344 mg of theophylline. Multiple doses of lomefloxacin had no effect on the area under the concentration-time curve from 0 h to infinity, maximal concentration, or clearance of theophylline from serum. There was a slight increase in the theophylline half-life from 6.72 ± 1.63 to 7.02 ± 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant. No change in theophylline dose is required when lomefloxacin therapy is instituted in a patient receiving theophylline.

UR - http://www.scopus.com/inward/record.url?scp=0024308445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024308445&partnerID=8YFLogxK

M3 - Article

C2 - 2675751

AN - SCOPUS:0024308445

VL - 33

SP - 1006

EP - 1008

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

ER -